1. Debiopharm Group™
Bridging discovery to market
© Debiopharm Group™ 2012

2. Debiopharm Group™
 Key expertise : drug development
 Founded in 1979, privately-owned, financially independent
 Based in Switzerland
 Lausanne (Headquarters)  Martigny  Swiss Technology
 Worldwide scouting  Applied research Institute
 Drug development  Formulation  R&D unit
 Biotech investment  GMP manufacturing  Bioanalytics
 Financial management
 Team : staff over 300
 Extensive international network of partners: over 400
2 © Debiopharm Group™ 2012

3. Debiopharm Group’s achievements
 Five products commercialised worldwide
Several Billion dollar sales (turnover ~ $ 2.7 B)
 Eloxatin® / Elplat® / Dacotin® / Dacplat®
 Decapeptyl® / Trelstar® / Pamorelin® 1-month
 Decapeptyl® / Trelstar® / Pamorelin® 3-month
 Decapeptyl® / Trelstar® 6-month
 Moapar® / Salvacyl® 3-month
3 © Debiopharm Group™ 2012

4. Four strategic priorities
:: Development of molecules
:: Redesign of molecules, innovative
formulations & peptide chemistry
Debiopharm
:: Companion diagnostics
Group & personalised medicine
:: Access to medicines
in emerging economies
4 © Debiopharm Group™ 2012

5. Business model: a bridge to develop therapies
Discovery DEBIOPHARM GROUP™ Market
Fully funded
Academic institutions drug development Pharma
Biotech & innovation
Start-up
Pharma
from molecule rapid and creative development to drug approval
5 © Debiopharm Group™ 2012

6. Main International Partners: Licensors…
 USA  China  India  Japan
 Ascenta Therapeutics  Press release  Aurigene  Nagoya City
soon University
 Curis
 Mercury Therapeutics Inc.
 MSM Protein Technologies
 Tulane University
 Yale University
…all over the world
6 © Debiopharm Group™ 2012

7. Main International Partners: Licensees…
 Sanofi
 Novartis
 Pfizer Inc.
 Watson Pharmaceuticals
 Yakult
 Ipsen
 Aché
 Dr. Reddy’s Laboratories
 Ferring
 Tecnofarma
…covering the entire world
7 © Debiopharm Group™ 2012

8. What we are looking for
 Small molecules  Therapeutic areas
 Biologics:  Oncology: innovative targets
 Peptides  Selected indications:
 Infection
 Proteins
 Metabolism
 siRNAs  Immunology
8 © Debiopharm Group™ 2012

9. GMP Manufacturing, Formulation and Fill & Finish
 Formulation
 Redesign of molecules (Debio025 / anti-HCV)
 Peptide chemistry
 Innovative formulations: oral delivery, SR (PLGA-based)
 Drug vials
 Bulk manufacturing
 Distributed worldwide
 Facilities
 FDA & Swissmedic inspected
9 © Debiopharm Group™ 2012

10. Debiopharm Group™ Pipeline
Preclinical
Submitted
Phase III
Phase II
Phase I
Debio 025 - HCV,Cyclophilin inhibitor (worldwide licence to Novartis except JPN)
Debio 8206 CPP - TRI 6M, Central Precocious Puberty
Debio 8206 SC - TRI 6M, GnrH agonist, Prostate cancer
Debio 0932 - Oncology, Hsp90 inhibitor
Debio 1143 - Oncology, SMAC mimetic (pro-apoptotic)
Debio 025 - HCV,Cyclophilin inhibitor, Japan
yDebio 1036 - Autoimmune diseases, undisclosed target
yDebio 0617 - Oncology, undisclosed target
Debio 0930 - Metabolic diseases, AMPK activator
yy
Debio 0929 - Oncology, undisclosed target
Debio 0826 - Oncology, undisclosed target
Debio 1141 - Urothelial carcinoma, siRNA
10 Debio 1142 - Oncology, undisclosed target © Debiopharm Group™ 2012

11. 10 reasons to partner with Debiopharm Group
1. Financial strength and independence
2. Creativity, adaptability, flexibility
3. Full development expertise: preclinical, clinical, formulation
& Life Cycle Management, etc.
4. Entrepreneurial and start-up mindset
5. Stable top management
6. Rapid decision-making
7. Long term vision
8. Strong & long-lasting partnerships
9. Risk mitigation strategies: out-licensing at phase II / Phase III
10. Discoverer benefits from the financial success
11 © Debiopharm Group™ 2012

12. Debiopharm Group’s team builds the future
Richard Juilliart - 2010
12 © Debiopharm Group™ 2012

13. Contact us
Debiopharm Group™ Headquarters
Forum “après-demain”
Chemin Messidor 5-7
CP 5911, CH - 1002 Lausanne
Switzerland
Tel. +41 (0)21 321 01 11
Fax +41 (0)21 321 01 69
www.debiopharm.com
Photo: Jacques Straesslé
Maurice Wagner
Director Corporate Affairs & Communication
mwagner@debiopharm.com
13 © Debiopharm Group™ 2012